Meloxicam (Mobic): A review of its pharmacological and clinical profile

Folia Pharmacologica Japonica

Volumn 120, Issue 6, 2002, Pages 391-397

  Ogino, Keiko ^a   Saito, Kazushige ^a   Osugi, Takeshi ^a   Satoh, Hisashi ^a  

^a NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

Author keywords

Cyclooxygenase (COX) 2; Meloxicam; Mobic; Non steroidal anti inflammatory drugs; Prostaglandins

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; INDOMETACIN; MELOXICAM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; BLEEDING TIME; DRUG EFFICACY; DRUG INDICATION; DRUG SELECTIVITY; GASTROINTESTINAL TOXICITY; HUMAN; NONHUMAN; REVIEW; THROMBOCYTE AGGREGATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; CYCLOOXYGENASE 2; ENZYME INHIBITORS; GASTRIC MUCOSA; GASTROINTESTINAL HEMORRHAGE; HUMANS; INFLAMMATION; ISOENZYMES; MEMBRANE PROTEINS; PAIN; PLATELET AGGREGATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; THIAZINES; THIAZOLES;

EID: 0036913029     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.120.391     Document Type: Review

References (18)

1. Xie W, Chipman JG, Robertson DL, Erikson RL and Simmons DL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88, 2692-2696 (1991)
2. Kujubu DA, Fletcher BS, Varnum BC, Lim RW and Herschman HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase. J Biol Chem 266, 12866-12872 (1991)
3. Herschman HR: Prostaglandin synthase 2. Biochim Biophys Acta 1299, 125-140 (1996)
4. Ogino K, Hatanaka K, Kawamura M, Katori M and Harada Y: Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1. Pharmacology 55, 44-53 (1997)
5. Engelhardt G, Bogel R, Schnitzer C and Utzmann R: Meloxicam: Influence on arachidonic acid metabolism. Part 1. In vitro findings. Biochem Pharmacol 51, 21-28 (1996)
6. Pairet M, van Ryn J, Schierok H, Mauz A, Trummlitz G and Engelhardt G: Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4′-isomer. Inflamm Res 47, 270-276 (1998)
7. Kawai S: Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various nonsteroidal anti-inflammatory drugs: A clinical consideration. Inflamm Res 47, S102-S106 (1998)
8. Engelhardt G, Homma D, Schlegel K, Utzmann R and Schnitzler C: Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 44, 423-433 (1995)
9. Engelhardt G, Homma D and Schnitzler C: Meloxicam: A potent inhibitor of adjuvant arthritis in the Lewis rat. Inflamm Res 44, 548-555 (1995)
10. Rinder HM, Gagnier RP, Leonard J and Wood CC: Bleeding time and platelet function in normal volunteers receiving meloxicam. William Harvey Res Conf 'Progress in the Field of Selective COX-2 Inhibitors' (2001)
11. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA and Vane JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci USA 96, 7563-7568 (1999)
12. Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, Begaud B, Dequeker J, Isomaki H, Littlejohn G, Mau J, et al: Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 37, 937-945 (1998)
13. Dequeker J, Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, Begaud B, Isomaki H, Littlejohn G, Mau J, et al: Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: Results of the Safety and Efficacy Largescale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 37, 946-951 (1998)
14. Distel M, Mueller C, Bluhmki E and Fries J: Safety of meloxicam: A global analysis of clinical trials. Br J Rheumatol 35, 68-77 (1996)